What did @abcnewslive actually say?
Dr. Darien Sutton, an ER physician, told ABC News that peptides are "small pieces of proteins that act as messengers in the body" and that unregulated injectable peptides carry risks including infection, bacterial contamination, hormone disruption, and potentially "increasing the development of abnormal cells" — which he called "the basis for cancer." He also acknowledged over 100 FDA-approved peptide-based medications exist, including insulin and GLP-1 receptor agonists, and drew a hard line between those and off-market peptides sold on social media. His bottom line: if you use peptides at all, do it under physician supervision.
This was a mainstream news segment aimed at a general audience, not a clinical audience. That context matters when evaluating how precise — or imprecise — the claims actually were.
Does the science back this up?
Mostly, yes, with some important caveats. The contamination and infection risks are well-documented and not theoretical. The cancer claim is the most scientifically contested part of the segment.
On contamination: a 2023 analysis by Valisure found significant quality and labeling inconsistencies in peptide products sold through gray-market channels, consistent with Dr. Sutton's concern about "uncertainty of what you're injecting." Injectable peptides sourced outside a licensed pharmacy carry real sterility risks.
On off-target pathway activation: this is legitimate pharmacology. Peptides interact with receptor systems that are not fully mapped in humans. BPC-157, for example, has shown pro-angiogenic effects in animal models (Chang et al., 2011, Journal of Applied Physiology), which in theory could influence tumor vascularity. However, no peer-reviewed human study has established a causal link between any of the commonly marketed peptides and human cancer incidence. The risk is plausible, not proven. Framing it as "the basis for cancer" overstates the current evidence base.
On GLP-1s and insulin as peptide-based medications: accurate. Semaglutide, liraglutide, and insulin are all peptide-derived. Dr. Sutton is correct that FDA approval involves rigorous efficacy and long-term safety review that off-market peptides simply have not undergone.
What did they get wrong (or right)?
Dr. Sutton got the foundational science right and the regulatory framing right. Peptides are messengers. Unregulated injectables are genuinely risky. FDA-approved peptides went through trials that gray-market products did not. These are not controversial statements.
Where the segment oversimplified: the cancer claim. Saying that off-target pathway activation "can run the risk of increasing the development of abnormal cells" and immediately labeling that "the basis for cancer" is a logical leap that the current human evidence does not fully support. Animal studies on peptides like TB-500 (thymosin beta-4) do show effects on cell migration and proliferation, which can cut both ways — some research has explored its role in tissue repair, while theoretical oncological concerns exist. But conflating a mechanistic possibility with a clinical outcome, without qualifying the evidence level, is the kind of thing that turns a legitimate caution into a scare claim.
To be fair to Dr. Sutton: he is an ER physician speaking to a mass audience, not publishing in a journal. Flagging plausible long-term risks is appropriate in that context. But precision matters, and the cancer framing was imprecise.
What should you actually know?
The regulatory gap Dr. Sutton describes is real and consequential. In 2023, the FDA removed several peptides including BPC-157 and TB-500 from the list of substances eligible for compounding, citing a lack of clinical evidence. That is a regulatory fact, not an opinion.
Here is what that means practically. A peptide sourced from a licensed compounding pharmacy operating under FDA oversight is a different product, with different quality standards, than one ordered from a research chemical supplier. They are not equivalent. Anyone using peptides should be asking where the product was manufactured, whether it was tested for sterility and potency, and whether the prescribing provider understands the pharmacology well enough to monitor for complications.
The absence of robust human trials does not mean peptides are uniformly ineffective. It means the risk-benefit calculation cannot be made with the same confidence as for approved drugs. A provider who tells you otherwise is selling you certainty the data does not support.
- If you are considering peptide therapy, use a regulated telehealth or clinical platform that sources from licensed compounding pharmacies.
- Ask your provider specifically what studies informed the protocol they are recommending.
- Understand that "research peptide" products sold online are not pharmaceutical grade and carry contamination risks.
- Long-term safety data for most marketed peptides simply does not exist in humans.